| Symbol | OCUL |
|---|---|
| Name | OCULAR THERAPEUTIX, INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 15 CROSBY DRIVE, BEDFORD, MA 01730 |
| Telephone | 781-357-4000 |
| Fax | — |
| — | |
| Website | https://www.ocutx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001393434 |
| Description | Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Additional info from NASDAQ: |
2026-06-12 21:23
Director Warden Charles M 🟢 acquired 58.0K shares (1 derivative) of OCULAR THERAPEUTIX, INC (OCUL) at $8.74 Transaction Date: Jun 10, 2026 | Filing ID: 073589
Read more
2026-06-12 21:22
Director Graves Adrienne L 🟢 acquired 58.0K shares (1 derivative) of OCULAR THERAPEUTIX, INC (OCUL) at $8.74 Transaction Date: Jun 10, 2026 | Filing ID: 073587
Read more
2026-06-12 21:22
Robins Jason Shand 🟢 acquired 29.5K shares (1 derivative) of OCULAR THERAPEUTIX, INC (OCUL) at $8.74 Transaction Date: Jun 10, 2026 | Filing ID: 073586
Read more
2026-06-12 21:21
Director Hong Seung Suh 🟢 acquired 58.0K shares (1 derivative) of OCULAR THERAPEUTIX, INC (OCUL) at $8.74 Transaction Date: Jun 10, 2026 | Filing ID: 073585
Read more
2026-06-12 21:20
Director LINDSTROM RICHARD L MD 🟢 acquired 58.0K shares (1 derivative) of OCULAR THERAPEUTIX, INC (OCUL) at $8.74 Transaction Date: Jun 10, 2026 | Filing ID: 073584
Read more
2026-06-12 21:19
Director RAINES MERILEE 🟢 acquired 58.0K shares (1 derivative) of OCULAR THERAPEUTIX, INC (OCUL) at $8.74 Transaction Date: Jun 10, 2026 | Filing ID: 073582
Read more
2026-06-12 21:19
Director Williams Leslie J. 🟢 acquired 58.0K shares (1 derivative) of OCULAR THERAPEUTIX, INC (OCUL) at $8.74 Transaction Date: Jun 10, 2026 | Filing ID: 073580
Read more
2026-06-12 20:23
(99% Neutral) OCULAR THERAPEUTIX, INC (OCUL) Announces New Board Appointment
Read more
2026-06-05 20:01
Waheed Nadia 🔴 sold 14.8K shares of OCULAR THERAPEUTIX, INC (OCUL) at $8.27 Transaction Date: Jun 03, 2026 | Filing ID: 070956
Read more
2026-06-05 11:00
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT02309736 | OTX-14-002: Device Exposure Registry | — | Endophthalmitis | Withdrawn | — | — | ClinicalTrials.gov |
| NCT07516132 | Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) i… | Phase3 | Neovascular Age-Related Macular Degeneration (nAMD) | Not_Yet_Recruiting | 2026-04-01 | 2030-08-01 | ClinicalTrials.gov |
| NCT07235085 | A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Pa… | Phase3 | Non-Proliferative Diabetic Retinopathy | Recruiting | 2025-11-17 | 2027-03-01 | ClinicalTrials.gov |
| NCT06495918 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Imp… | Phase3 | Neovascular Age-related Macular Degeneration | Active_Not_Recruiting | 2024-11-27 | 2027-01-08 | ClinicalTrials.gov |
| NCT06223958 | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Thera… | Phase3 | Neovascular Age-Related Macular Degeneration | Active_Not_Recruiting | 2024-01-29 | 2027-09-27 | ClinicalTrials.gov |
| NCT05814757 | OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED) | Phase2 | Dry Eye Syndromes | Completed | 2023-05-11 | 2024-05-22 | ClinicalTrials.gov |
| NCT05695417 | Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects… | Phase1 | Non-proliferative Diabetic Retinopathy | Unknown | 2023-01-15 | 2024-12-01 | ClinicalTrials.gov |
| NCT05372315 | Efficacy of Dextenza Insert in Upper vs Lower Punctum Following Cataract Surger… | Phase4 | Cataract | Completed | 2022-06-15 | 2022-10-31 | ClinicalTrials.gov |
| NCT05307081 | An Observational, Qualitative Study Assessing Eye Drop Administration | — | Ocular Injury | Unknown | 2022-04-21 | 2023-12-01 | ClinicalTrials.gov |
| NCT05335122 | A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracamera… | Phase2 | Open Angle Glaucoma | Completed | 2022-03-16 | 2025-01-24 | ClinicalTrials.gov |
| NCT05143281 | The SITE Study - Dexamethasone Ophthalmic Insert In OR on Day of Surgery Versus… | Phase4 | Cataract | Completed | 2021-12-13 | 2023-02-01 | ClinicalTrials.gov |
| NCT05116345 | DEXTENZA for the Treatment of Pain and Inflammation Following Surgical Trabecul… | Phase4 | Glaucoma Following Surgery | Unknown | 2021-11-01 | 2023-11-01 | ClinicalTrials.gov |
| NCT04728646 | Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surfa… | Phase4 | Graft Vs Host Disease | Withdrawn | 2021-09-01 | 2021-12-13 | ClinicalTrials.gov |
| NCT05023304 | In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery | Phase4 | Cataract | Completed | 2021-08-23 | 2022-10-01 | ClinicalTrials.gov |
| NCT04989699 | Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-rel… | Phase1 | Neovascular Age-Related Macular Degeneration | Completed | 2021-07-28 | 2023-12-18 | ClinicalTrials.gov |
| NCT04945824 | A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in … | Early_Phase1 | Healthy | Terminated | 2021-06-01 | 2022-11-01 | ClinicalTrials.gov |
| NCT04708821 | DEXTENZA Therapy for Treatment of Allergic Conjunctivitis | Phase4 | Bilateral Conjunctivitis (Disorder) | Completed | 2021-04-30 | 2021-09-02 | ClinicalTrials.gov |
| NCT04863742 | Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mil… | Phase4 | Dry Eye Syndromes | Unknown | 2021-04-26 | 2021-09-30 | ClinicalTrials.gov |
| NCT04529512 | INtravitreal and Aqueous Dexamethasone Levels After DEXtenza | Phase4 | Ocular Disease Requiring Surgery | Unknown | 2021-03-01 | 2021-03-01 | ClinicalTrials.gov |
| NCT04747977 | To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Si… | Phase2 | Dry Eye | Completed | 2021-02-12 | 2021-09-22 | ClinicalTrials.gov |
| NCT04530864 | Pre-Surgical Ocular Surface Treatment With Intracanalicular Dexamethasone Inser… | Phase4 | Dry Eye Disease | Unknown | 2021-01-01 | 2021-07-01 | ClinicalTrials.gov |
| NCT04563299 | Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing … | Phase4 | Neovascular Age-related Macular Degeneration | Terminated | 2020-12-09 | 2023-02-14 | ClinicalTrials.gov |
| NCT04687800 | Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery S… | Phase4 | Cataract | Terminated | 2020-12-01 | 2022-10-24 | ClinicalTrials.gov |
| NCT04563559 | PREFERENTIAL Study | Phase2 | Cataract Surgery | Withdrawn | 2020-11-01 | 2021-11-01 | ClinicalTrials.gov |
| NCT04403516 | Dextenza in Pterygium Surgery | Phase4 | Pterygium | Completed | 2020-10-01 | 2021-08-05 | ClinicalTrials.gov |
| NCT04539548 | A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocu… | Phase3 | Cataract | Completed | 2020-09-04 | 2023-12-21 | ClinicalTrials.gov |
| NCT04527887 | Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Dis… | Phase4 | Dry Eye | Terminated | 2020-09-04 | 2024-12-31 | ClinicalTrials.gov |
| NCT04413253 | Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease | Phase4 | Dry Eye Syndromes | Terminated | 2020-08-01 | 2022-04-11 | ClinicalTrials.gov |
| NCT04413279 | Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Disease | Phase4 | Dry Eye Syndromes | Completed | 2020-08-01 | 2021-07-01 | ClinicalTrials.gov |
| NCT04464629 | Assessing the Efficacy and Safety of DEXTENZA in Pseudo Phakic Patients Undergo… | Phase4 | Retinal Detachment | Terminated | 2020-07-14 | 2023-01-25 | ClinicalTrials.gov |
| NCT04426734 | Evaluation of DEXTENZA in the Management of Pain and Inflammation in Patients W… | Phase4 | Non-infectious Anterior Uveitis | Unknown | 2020-07-01 | 2021-03-31 | ClinicalTrials.gov |
| NCT04396990 | The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospectiv… | Phase4 | Refractive Surgery | Completed | 2020-06-08 | 2020-09-28 | ClinicalTrials.gov |
| NCT04371445 | Dextenza in the Post-op Management of Vitreoretinal Surgeries | Phase4 | Vitreoretinal Surgery | Recruiting | 2020-06-01 | 2026-05-01 | ClinicalTrials.gov |
| NCT04362670 | Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects… | Phase1 | Dry Eye Disease | Completed | 2020-04-23 | 2021-08-11 | ClinicalTrials.gov |
| NCT04168112 | Intracanalicular Dexamethasone Insert for Post-Corneal Cross-Linking Inflammati… | Phase4 | Keratoconus, Unstable | Completed | 2020-02-12 | 2023-04-05 | ClinicalTrials.gov |
| NCT04200651 | Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS a… | Phase4 | Glaucoma | Terminated | 2020-01-13 | 2023-07-12 | ClinicalTrials.gov |
| NCT04462523 | DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vit… | Phase4 | Vitreo-Retinal Surgery | Completed | 2020-01-03 | 2022-03-31 | ClinicalTrials.gov |
| NCT04316936 | Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Ac… | Phase4 | Cataract Surgery | Completed | 2019-12-10 | 2020-12-23 | ClinicalTrials.gov |
| NCT04205916 | A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery | Phase4 | Patient Preference | Recruiting | 2019-11-04 | 2020-12-01 | ClinicalTrials.gov |
| NCT04050865 | A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Aller… | Phase3 | Allergic Conjunctivitis | Completed | 2019-08-05 | 2020-02-28 | ClinicalTrials.gov |
| NCT03630315 | CLN-0046: Treatment of AMD Subjects With OTX-TKI | Phase1 | Neovascular Age-related Macular Degeneration | Completed | 2019-02-18 | 2024-01-10 | ClinicalTrials.gov |
| NCT04061044 | A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travopros… | Phase3 | Open Angle Glaucoma and Ocular Hypertension | Completed | 2018-07-10 | 2020-09-22 | ClinicalTrials.gov |
| NCT04360174 | CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glauc… | Phase1 | Ocular Hypertension | Completed | 2018-04-25 | 2021-05-24 | ClinicalTrials.gov |
| NCT02914509 | Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or … | Phase3 | Open Angle Glaucoma | Completed | 2016-11-07 | 2019-03-30 | ClinicalTrials.gov |
| NCT02736175 | OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for th… | Phase3 | Post-Surgical Ocular Pain | Completed | 2015-10-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02988882 | OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for th… | Phase3 | Chronic Allergic Conjunctivitis | Completed | 2015-06-01 | 2016-04-27 | ClinicalTrials.gov |
| NCT02445326 | OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for th… | Phase3 | Chronic Allergic Conjunctivitis | Completed | 2015-04-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT02468700 | OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for th… | Phase2 | Dry Eye | Completed | 2015-01-01 | 2015-11-01 | ClinicalTrials.gov |
| NCT02310815 | ReSure Sealant Post Approval Study | — | Adverse Events | Completed | 2014-12-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT02312544 | Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Dro… | Phase2 | Glaucoma | Completed | 2014-11-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT02089113 | OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for th… | Phase3 | Post-Surgical Ocular Pain | Completed | 2014-04-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02062905 | OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for th… | Phase2 | Chronic Allergic Conjunctivitis | Completed | 2014-03-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02034019 | Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular … | Phase3 | Post Ocular Surgical Inflammation and Pain | Completed | 2014-02-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01845038 | Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment … | Phase1 | Glaucoma | Completed | 2013-04-01 | 2014-05-01 | ClinicalTrials.gov |
| NCT01800175 | Non-Significant Risk Feasibility Study to Assess Retention and Replacement of t… | Phase1 | Healthy Subjects | Unknown | 2013-02-01 | — | ClinicalTrials.gov |
| NCT01666210 | Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inf… | Phase2 | Ocular Inflammation and Pain | Completed | 2012-10-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01498224 | ReSure Sealant Pivotal Study | Phase3 | Cataract Surgery Incision Leak | Completed | 2011-12-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00774228 | I-ZIP Ocular Bandage Pivotal Study | Na | Cataract | Completed | 2008-10-01 | 2009-08-01 | ClinicalTrials.gov |
Total clinical trials: 58
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ReSure Sealant | Other | Preclinical | Adverse Events | COMPLETED | NCT02310815 |
| Timolol | Other | Phase PHASE2 | Glaucoma | COMPLETED | NCT02312544 |
| OTX-TP | Other | Phase PHASE2 | Glaucoma | COMPLETED | NCT02312544 |
| Placebo Vehicle | Other | Phase PHASE3 | Post-Surgical Ocular Pain | COMPLETED | NCT02736175 |
| Dexamethasone | Other | Phase PHASE3 | Post-Surgical Ocular Pain | COMPLETED | NCT02736175 |
| Punctum Plug | Other | Phase PHASE3 | Post Ocular Surgical Inflammation and Pain | COMPLETED | NCT02034019 |
| Dexamethasone | Other | Phase PHASE3 | Post Ocular Surgical Inflammation and Pain | COMPLETED | NCT02034019 |
| Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation | Other | Phase PHASE4 | Dry Eye Syndromes | COMPLETED | NCT04413279 |
| LipiFlow Thermal Pulsation | Other | Phase PHASE4 | Dry Eye Syndromes | COMPLETED | NCT04413279 |
| Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution | Other | Phase PHASE4 | Dry Eye Syndromes | TERMINATED | NCT04413253 |
| Lifitegrast 5% Ophthalmic Solution | Other | Phase PHASE4 | Dry Eye Syndromes | TERMINATED | NCT04413253 |
| Artificial Tears | Other | Preclinical | Ocular Injury | UNKNOWN | NCT05307081 |
| Punctum Plug | Other | Phase PHASE1 | Healthy Subjects | UNKNOWN | NCT01800175 |
| Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug | Drug | Phase PHASE1 | Glaucoma | COMPLETED | NCT01845038 |
| OTX-TPb ~3µg/day over 3 months with natural tears drops | Other | Phase PHASE1 | Glaucoma | COMPLETED | NCT01845038 |
| OTX-TPa ~4µg/day over 2 mos. with natural tears drops | Other | Phase PHASE1 | Glaucoma | COMPLETED | NCT01845038 |
| Sutures | Other | Phase PHASE3 | Cataract Surgery Incision Leak | COMPLETED | NCT01498224 |
| ReSure Sealant | Other | Phase PHASE3 | Cataract Surgery Incision Leak | COMPLETED | NCT01498224 |
| Placebo Vehicle | Other | Phase PHASE2 | Dry Eye | COMPLETED | NCT02468700 |
| Dexamethasone | Other | Phase PHASE2 | Dry Eye | COMPLETED | NCT02468700 |
| Placebo Vehicle | Other | Phase PHASE3 | Chronic Allergic Conjunctivitis | COMPLETED | NCT02445326 |
| Dexamethasone | Other | Phase PHASE3 | Chronic Allergic Conjunctivitis | COMPLETED | NCT02445326 |
| Placebo Vehicle | Other | Phase PHASE2 | Chronic Allergic Conjunctivitis | COMPLETED | NCT02062905 |
| Dexamethasone | Other | Phase PHASE2 | Chronic Allergic Conjunctivitis | COMPLETED | NCT02062905 |
| Placebo Vehicle | Other | Phase PHASE3 | Post-Surgical Ocular Pain | COMPLETED | NCT02089113 |
| Dexamethasone | Other | Phase PHASE3 | Post-Surgical Ocular Pain | COMPLETED | NCT02089113 |
| Standard of care surgery | Procedure | Phase PHASE4 | Patient Preference | RECRUITING | NCT04205916 |
| Dexamethasone | Other | Phase PHASE4 | Patient Preference | RECRUITING | NCT04205916 |
| ReSure Sealant | Other | Preclinical | Endophthalmitis | WITHDRAWN | NCT02309736 |
| Topical Prednisolone Acetate 1% | Other | Phase PHASE4 | Non-infectious Anterior Uveitis | UNKNOWN | NCT04426734 |
| Dextenza Dexamethasone Implant | Other | Phase PHASE4 | Non-infectious Anterior Uveitis | UNKNOWN | NCT04426734 |
| Placebo Vehicle | Other | Phase PHASE3 | Chronic Allergic Conjunctivitis | COMPLETED | NCT02988882 |
| Dexamethasone | Other | Phase PHASE3 | Chronic Allergic Conjunctivitis | COMPLETED | NCT02988882 |
| Dextenza 0.4Mg Ophthalmic Insert | Other | Phase PHASE4 | Dry Eye Disease | UNKNOWN | NCT04530864 |
| DEXTENZA® | Other | Phase PHASE4 | Ocular Disease Requiring Surgery | UNKNOWN | NCT04529512 |
| Prednisolone Acetate | Other | Phase PHASE4 | Dry Eye Syndromes | UNKNOWN | NCT04863742 |
| Dextenza 0.4Mg Ophthalmic Insert | Other | Phase PHASE4 | Dry Eye Syndromes | UNKNOWN | NCT04863742 |
| Placebo plug with no drug | Drug | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT04050865 |
| Dexamethasone, 0.4mg | Other | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT04050865 |
| Placebo Vehicle | Other | Phase PHASE3 | Open Angle Glaucoma | COMPLETED | NCT02914509 |
| Travoprost | Other | Phase PHASE3 | Open Angle Glaucoma | COMPLETED | NCT02914509 |
| Placebo Vehicle Punctum Plug | Other | Phase PHASE2 | Ocular Inflammation and Pain | COMPLETED | NCT01666210 |
| OTX-DP (Dexamethasone punctum plug) | Other | Phase PHASE2 | Ocular Inflammation and Pain | COMPLETED | NCT01666210 |
| Topical Dexamethasone | Other | Phase PHASE4 | Glaucoma Following Surgery | UNKNOWN | NCT05116345 |
| DEXTENZA | Other | Phase PHASE4 | Glaucoma Following Surgery | UNKNOWN | NCT05116345 |
| Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE] | Other | Phase PHASE2 | Cataract Surgery | WITHDRAWN | NCT04563559 |
| Dextenza 0.4Mg Ophthalmic Insert | Other | Phase PHASE2 | Cataract Surgery | WITHDRAWN | NCT04563559 |
| Regular dissolvable intracanalicular plug | Other | Phase PHASE4 | Graft Vs Host Disease | WITHDRAWN | NCT04728646 |
| DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use | Other | Phase PHASE4 | Graft Vs Host Disease | WITHDRAWN | NCT04728646 |
| Prednisolone Acetate 1% | Other | Phase PHASE4 | Pterygium | COMPLETED | NCT04403516 |
| Dexamethasone Intracanalicular Insert, 0.4mg | Other | Phase PHASE4 | Pterygium | COMPLETED | NCT04403516 |
| olopatadine hydrochloride ophthalmic solution 0.7% | Other | Phase PHASE4 | Bilateral Conjunctivitis (Disorder) | COMPLETED | NCT04708821 |
| 0.2% loteprednol etabonate ophthalmic suspension | Other | Phase PHASE4 | Bilateral Conjunctivitis (Disorder) | COMPLETED | NCT04708821 |
| Dexamethasone ophthalmic insert 0.4Mg | Other | Phase PHASE4 | Bilateral Conjunctivitis (Disorder) | COMPLETED | NCT04708821 |
| Durezol 0.05% Ophthalmic Emulsion | Other | Phase PHASE4 | Cataract | TERMINATED | NCT04687800 |
| Dextenza 0.4mg intracanalicular Insert | Other | Phase PHASE4 | Cataract | TERMINATED | NCT04687800 |
| Dilator | Other | Phase EARLY_PHASE1 | Healthy | TERMINATED | NCT04945824 |
| Dexamethasone Ophthalmic | Other | Phase EARLY_PHASE1 | Healthy | TERMINATED | NCT04945824 |
| OTX-DED | Other | Phase PHASE2 | Dry Eye | COMPLETED | NCT04747977 |
| Prednisolone Acetate | Other | Phase PHASE4 | Neovascular Age-related Macular Degeneration | TERMINATED | NCT04563299 |
| Dextenza 0.4Mg Ophthalmic Insert | Other | Phase PHASE4 | Neovascular Age-related Macular Degeneration | TERMINATED | NCT04563299 |
| Ophthalmic Insert | Other | Phase PHASE3 | Open Angle Glaucoma and Ocular Hypertension | COMPLETED | NCT04061044 |
| Topical Prednisolone | Other | Phase PHASE4 | Vitreo-Retinal Surgery | COMPLETED | NCT04462523 |
| Dextenza 0.4Mg Ophthalmic Insert | Other | Phase PHASE4 | Vitreo-Retinal Surgery | COMPLETED | NCT04462523 |
| Prednisolone Acetate 1% | Other | Phase PHASE4 | Cataract Surgery | COMPLETED | NCT04316936 |
| Dexycu, 9% Intraocular Suspension | Other | Phase PHASE4 | Cataract Surgery | COMPLETED | NCT04316936 |
| Dextenza (dexamethasone ophthalmic insert) 0.4mg | Other | Phase PHASE4 | Cataract Surgery | COMPLETED | NCT04316936 |
| Omidria | Other | Phase PHASE4 | Cataract Surgery | COMPLETED | NCT04316936 |
| Dexamethasone 0.4 MG [Dextenza] | Other | Phase PHASE4 | Cataract | COMPLETED | NCT05143281 |
| Prednisolone Acetate | Other | Phase PHASE4 | Retinal Detachment | TERMINATED | NCT04464629 |
| Dextenza | Other | Phase PHASE4 | Retinal Detachment | TERMINATED | NCT04464629 |
| Dextenza 0.4Mg Ophthalmic Insert | Other | Phase PHASE4 | Cataract | COMPLETED | NCT05372315 |
| Placebo Vehicle | Other | Phase PHASE1 | Dry Eye Disease | COMPLETED | NCT04362670 |
| OTX-CSI | Other | Phase PHASE1 | Dry Eye Disease | COMPLETED | NCT04362670 |
| Sham | Other | Phase PHASE1 | Non-proliferative Diabetic Retinopathy | UNKNOWN | NCT05695417 |
| OTX-TKI | Other | Phase PHASE1 | Non-proliferative Diabetic Retinopathy | UNKNOWN | NCT05695417 |
| Aflibercept/Sham | Other | Phase PHASE1 | Neovascular Age-Related Macular Degeneration | COMPLETED | NCT04989699 |
| OTX-TKI/Sham | Other | Phase PHASE1 | Neovascular Age-Related Macular Degeneration | COMPLETED | NCT04989699 |
| Prednisolone Acetate | Other | Phase PHASE4 | Keratoconus, Unstable | COMPLETED | NCT04168112 |
| Dextenza | Other | Phase PHASE4 | Keratoconus, Unstable | COMPLETED | NCT04168112 |
| Prednisolone Acetate 1% Oph Susp | Other | Phase PHASE4 | Glaucoma | TERMINATED | NCT04200651 |
| Dexamethasone Ophthalmic Insert | Other | Phase PHASE4 | Glaucoma | TERMINATED | NCT04200651 |
| Prednisolone acetate ophthalmic suspension USP 1% | Other | Phase PHASE3 | Cataract | COMPLETED | NCT04539548 |
| Dextenza Ophthalmic Insert | Other | Phase PHASE3 | Cataract | COMPLETED | NCT04539548 |
| Collagen Punctal Plug | Other | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT05814757 |
| Controlled Insertion | Other | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT05814757 |
| OTX-DED | Other | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT05814757 |
| Anti-VEGF | Other | Phase PHASE1 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT03630315 |
| OTX-TKI | Other | Phase PHASE1 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT03630315 |
| Topical Prednisolone | Other | Phase PHASE4 | Refractive Surgery | COMPLETED | NCT04396990 |
| Dextenza 0.4Mg Ophthalmic Insert | Other | Phase PHASE4 | Refractive Surgery | COMPLETED | NCT04396990 |
| OTX-TIC | Other | Phase PHASE1 | Ocular Hypertension | COMPLETED | NCT04360174 |
| ProLong™ collagen plugs | Other | Phase PHASE4 | Dry Eye | TERMINATED | NCT04527887 |
| Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg) | Other | Phase PHASE4 | Dry Eye | TERMINATED | NCT04527887 |
| Durysta, Bimatoprost Intracameral Implant 10 µg | Other | Phase PHASE2 | Open Angle Glaucoma | COMPLETED | NCT05335122 |
| OTX-TIC high dose Travoprost Intracameral Implant | Other | Phase PHASE2 | Open Angle Glaucoma | COMPLETED | NCT05335122 |
| OTX-TIC low dose Travoprost Intracameral Implant | Other | Phase PHASE2 | Open Angle Glaucoma | COMPLETED | NCT05335122 |
| Aflibercept | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06223958 |
| OTX-TKI (axitinib implant) | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06223958 |
| Aflibercept | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06495918 |
| OTX-TKI | Other | Phase PHASE3 | Neovascular Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06495918 |
| Topical prednisolone acetate | Other | Phase PHASE4 | Cataract | COMPLETED | NCT05023304 |
| Dextenza 0.4Mg Ophthalmic Insert | Other | Phase PHASE4 | Cataract | COMPLETED | NCT05023304 |
| Prednisolone Acetate 1% Oph Susp | Other | Phase PHASE4 | Vitreoretinal Surgery | RECRUITING | NCT04371445 |
| Dexamethasone Ophthalmic Insert | Other | Phase PHASE4 | Vitreoretinal Surgery | RECRUITING | NCT04371445 |
| Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24 | Procedure | Phase PHASE3 | Non-Proliferative Diabetic Retinopathy | RECRUITING | NCT07235085 |
| Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 | Other | Phase PHASE3 | Non-Proliferative Diabetic Retinopathy | RECRUITING | NCT07235085 |
| Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 | Procedure | Phase PHASE3 | Non-Proliferative Diabetic Retinopathy | RECRUITING | NCT07235085 |
| OTX-TKI | Other | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | NOT_YET_RECRUITING | NCT07516132 |
| Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24 | OTHER | Phase PHASE3 | Non-Proliferative Diabetic Retinopathy | RECRUITING | NCT07235085 |
| Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24 | DRUG | Phase PHASE3 | Non-Proliferative Diabetic Retinopathy | RECRUITING | NCT07235085 |
| Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24 | DRUG | Phase PHASE3 | Non-Proliferative Diabetic Retinopathy | RECRUITING | NCT07235085 |
| Aflibercept | DRUG | Phase PHASE3 | Neovascular Age-related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06495918 |
| OTX-TKI (axitinib implant) | DRUG | Phase PHASE3 | Neovascular Age-Related Macular Degeneration | ACTIVE_NOT_RECRUITING | NCT06223958 |
| Collagen Punctal Plug | DRUG | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT05814757 |
| Controlled Insertion | DRUG | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT05814757 |
| Sham | DRUG | Phase PHASE1 | Non-proliferative Diabetic Retinopathy | ACTIVE_NOT_RECRUITING | NCT05695417 |
| Durysta, Bimatoprost Intracameral Implant 10 µg | DRUG | Phase PHASE2 | Open Angle Glaucoma | COMPLETED | NCT05335122 |
| OTX-TIC high dose Travoprost Intracameral Implant | DRUG | Phase PHASE2 | Open Angle Glaucoma | COMPLETED | NCT05335122 |
| OTX-TIC low dose Travoprost Intracameral Implant | DRUG | Phase PHASE2 | Open Angle Glaucoma | COMPLETED | NCT05335122 |
| Artificial Tears | DRUG | Preclinical | Ocular Injury | UNKNOWN | NCT05307081 |
| Dexamethasone 0.4 MG [Dextenza] | DRUG | Phase PHASE4 | Cataract | COMPLETED | NCT05143281 |
| Topical Dexamethasone | DRUG | Phase PHASE4 | Glaucoma Following Surgery | UNKNOWN | NCT05116345 |
| DEXTENZA | DRUG | Phase PHASE4 | Glaucoma Following Surgery | UNKNOWN | NCT05116345 |
| Topical prednisolone acetate | DRUG | Phase PHASE4 | Cataract | COMPLETED | NCT05023304 |
| Aflibercept/Sham | DRUG | Phase PHASE1 | Neovascular Age-Related Macular Degeneration | COMPLETED | NCT04989699 |
| OTX-TKI/Sham | DRUG | Phase PHASE1 | Neovascular Age-Related Macular Degeneration | COMPLETED | NCT04989699 |
| Dilator | DEVICE | Phase EARLY_PHASE1 | Healthy | TERMINATED | NCT04945824 |
| Dexamethasone Ophthalmic | DRUG | Phase EARLY_PHASE1 | Healthy | TERMINATED | NCT04945824 |
| OTX-DED | DRUG | Phase PHASE2 | Dry Eye Syndromes | COMPLETED | NCT05814757 |
| Regular dissolvable intracanalicular plug | DEVICE | Phase PHASE4 | Graft Vs Host Disease | WITHDRAWN | NCT04728646 |
| DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use | DRUG | Phase PHASE4 | Graft Vs Host Disease | WITHDRAWN | NCT04728646 |
| olopatadine hydrochloride ophthalmic solution 0.7% | DRUG | Phase PHASE4 | Bilateral Conjunctivitis (Disorder) | COMPLETED | NCT04708821 |
| 0.2% loteprednol etabonate ophthalmic suspension | DRUG | Phase PHASE4 | Bilateral Conjunctivitis (Disorder) | COMPLETED | NCT04708821 |
| Dexamethasone ophthalmic insert 0.4Mg | DRUG | Phase PHASE4 | Bilateral Conjunctivitis (Disorder) | COMPLETED | NCT04708821 |
| Durezol 0.05% Ophthalmic Emulsion | DRUG | Phase PHASE4 | Cataract | TERMINATED | NCT04687800 |
| Dextenza 0.4mg intracanalicular Insert | DRUG | Phase PHASE4 | Cataract | TERMINATED | NCT04687800 |
| Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE] | DRUG | Phase PHASE2 | Cataract Surgery | WITHDRAWN | NCT04563559 |
| Prednisolone acetate ophthalmic suspension USP 1% | DRUG | Phase PHASE3 | Cataract | COMPLETED | NCT04539548 |
| Dextenza Ophthalmic Insert | DRUG | Phase PHASE3 | Cataract | COMPLETED | NCT04539548 |
| DEXTENZA® | DRUG | Phase PHASE4 | Ocular Disease Requiring Surgery | UNKNOWN | NCT04529512 |
| ProLong™ collagen plugs | OTHER | Phase PHASE4 | Dry Eye | TERMINATED | NCT04527887 |
| Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg) | DRUG | Phase PHASE4 | Dry Eye | TERMINATED | NCT04527887 |
| Topical Prednisolone Acetate 1% | DRUG | Phase PHASE4 | Non-infectious Anterior Uveitis | UNKNOWN | NCT04426734 |
| Dextenza Dexamethasone Implant | DEVICE | Phase PHASE4 | Non-infectious Anterior Uveitis | UNKNOWN | NCT04426734 |
| Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation | DRUG | Phase PHASE4 | Dry Eye Syndromes | COMPLETED | NCT04413279 |
| LipiFlow Thermal Pulsation | PROCEDURE | Phase PHASE4 | Dry Eye Syndromes | COMPLETED | NCT04413279 |
| Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution | DRUG | Phase PHASE4 | Dry Eye Syndromes | TERMINATED | NCT04413253 |
| Lifitegrast 5% Ophthalmic Solution | DRUG | Phase PHASE4 | Dry Eye Syndromes | TERMINATED | NCT04413253 |
| Dexamethasone Intracanalicular Insert, 0.4mg | DRUG | Phase PHASE4 | Pterygium | COMPLETED | NCT04403516 |
| Topical Prednisolone | DRUG | Phase PHASE4 | Vitreo-Retinal Surgery | COMPLETED | NCT04462523 |
| Dextenza 0.4Mg Ophthalmic Insert | DRUG | Phase PHASE4 | Cataract | COMPLETED | NCT05372315 |
| OTX-CSI | DRUG | Phase PHASE1 | Dry Eye Disease | COMPLETED | NCT04362670 |
| OTX-TIC | DRUG | Phase PHASE1 | Ocular Hypertension | COMPLETED | NCT04360174 |
| Prednisolone Acetate 1% | DRUG | Phase PHASE4 | Pterygium | COMPLETED | NCT04403516 |
| Dexycu, 9% Intraocular Suspension | DRUG | Phase PHASE4 | Cataract Surgery | COMPLETED | NCT04316936 |
| Dextenza (dexamethasone ophthalmic insert) 0.4mg | DRUG | Phase PHASE4 | Cataract Surgery | COMPLETED | NCT04316936 |
| Omidria | DRUG | Phase PHASE4 | Cataract Surgery | COMPLETED | NCT04316936 |
| Standard of care surgery | OTHER | Phase PHASE4 | Patient Preference | RECRUITING | NCT04205916 |
| Prednisolone Acetate 1% Oph Susp | DRUG | Phase PHASE4 | Vitreoretinal Surgery | RECRUITING | NCT04371445 |
| Dexamethasone Ophthalmic Insert | DRUG | Phase PHASE4 | Vitreoretinal Surgery | RECRUITING | NCT04371445 |
| Prednisolone Acetate | DRUG | Phase PHASE4 | Dry Eye Syndromes | UNKNOWN | NCT04863742 |
| Dextenza | DRUG | Phase PHASE4 | Retinal Detachment | TERMINATED | NCT04464629 |
| Ophthalmic Insert | DRUG | Phase PHASE3 | Open Angle Glaucoma and Ocular Hypertension | COMPLETED | NCT04061044 |
| Placebo plug with no drug | DEVICE | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT04050865 |
| Dexamethasone, 0.4mg | DRUG | Phase PHASE3 | Allergic Conjunctivitis | COMPLETED | NCT04050865 |
| Anti-VEGF | DRUG | Phase PHASE1 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT03630315 |
| OTX-TKI | DRUG | Phase PHASE3 | Neovascular Age-Related Macular Degeneration (nAMD) | NOT_YET_RECRUITING | NCT07516132 |
| Travoprost | DRUG | Phase PHASE3 | Open Angle Glaucoma | COMPLETED | NCT02914509 |
| Timolol | DRUG | Phase PHASE2 | Glaucoma | COMPLETED | NCT02312544 |
| OTX-TP | DRUG | Phase PHASE2 | Glaucoma | COMPLETED | NCT02312544 |
| Placebo Vehicle Punctum Plug | DRUG | Phase PHASE2 | Ocular Inflammation and Pain | COMPLETED | NCT01666210 |
| OTX-DP (Dexamethasone punctum plug) | DRUG | Phase PHASE2 | Ocular Inflammation and Pain | COMPLETED | NCT01666210 |
| Placebo Vehicle | OTHER | Phase PHASE1 | Dry Eye Disease | COMPLETED | NCT04362670 |
| Dexamethasone | DRUG | Phase PHASE4 | Patient Preference | RECRUITING | NCT04205916 |
| Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug | DRUG | Phase PHASE1 | Glaucoma | COMPLETED | NCT01845038 |
| OTX-TPb ~3µg/day over 3 months with natural tears drops | DRUG | Phase PHASE1 | Glaucoma | COMPLETED | NCT01845038 |
| OTX-TPa ~4µg/day over 2 mos. with natural tears drops | DRUG | Phase PHASE1 | Glaucoma | COMPLETED | NCT01845038 |
| Punctum Plug | DRUG | Phase PHASE3 | Post Ocular Surgical Inflammation and Pain | COMPLETED | NCT02034019 |
| Sutures | PROCEDURE | Phase PHASE3 | Cataract Surgery Incision Leak | COMPLETED | NCT01498224 |
| ReSure Sealant | DEVICE | Preclinical | Adverse Events | COMPLETED | NCT02310815 |
| Oasis 24 Hour Soft Shield Collagen Corneal Shield | DEVICE | Approved | Cataract | COMPLETED | NCT00774228 |
| I-ZIP Ocular Bandage | DEVICE | Approved | Cataract | COMPLETED | NCT00774228 |
Total products: 183